HiNounou awarded Winner of Bayer’s Grants4Apps Shanghai 2017 Accelerator Program

HiNounou awarded Winner of Bayer’s Grants4Apps Shanghai 2017 Accelerator Program

Out of more than 130 health start-ups in China, HiNounou is selected as one of the 4 top start-ups in Bayer's Grants4Apps Shanghai 2017 Incubator Program, obtaining the chance to be involved in the 88-day program training in Bayer’s Shanghai Lujiazui office from August 28.

The startups are selected mainly in consideration of their structural attractiveness, performance, overall vision and development ambitions. The working environment provided by Bayer will support the startups, helping them effectively and efficiently launch their products into the marketplace.

Bayer Grants4Apps is a global open innovation initiative, launched in 2013 as a crowdsourcing program. It provides financial support to developers and startups for their software, hardware and technology projects, which contribute to improving health outcomes or pharmaceutical processes. In 2014, the crowdsourcing program was expanded with an accelerator, as a new model of open innovation in the digital health field.

Grants4Apps Shanghai was first launched in Shanghai in 2016, it is an 88-day program that will bring the best of China’s powerful innovation capabilities together with Bayer’s global reach. Startups, from China, whose products and services have the potential for creating value for physicians, patients and consumers were invited to submit their innovative project ideas.

“Since its launch in China in 2016, the Grants4Apps Shanghai Program has focused on nurturing start-ups with digital solutions that tackle a wide range of healthcare issues in China. Bayer is very excited to work with these intrepid innovators, and we look forward to helping the start-ups make progress on their ideas and go-to-market strategies. We believe such collaborations in this vibrant sector will help to contribute solutions for a better life for people in China.” said Celina Chew, President of Bayer Group Greater China.